Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Tianan Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7672-8394; OpenAlex author ID A5016874780, A5112700160. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 5 papers · 2023: 6 papers · 2024: none · 2025: 3 papers · 2026: 4 papers

Papers 25

  1. Nanoadjuvant-Mediated Electro-Immunotherapy Enhances Irreversible Electroporation for Pancreatic Cancer Treatment. Last author DOI 10.1002/adma.202520546↗
  2. High-voltage electrical pulses for pancreatic cancer treatment in the era of precision medicine. Last author DOI 10.1097/js9.0000000000003386↗
  3. Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer: A Retrospectively Observa… Co-author DOI 10.1097/sla.0000000000006600↗
  4. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Co-author DOI 10.1200/jco-26-01393↗
  5. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Co-author DOI 10.1016/j.canlet.2025.217658↗
  6. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Co-author DOI 10.1016/j.ccell.2025.09.009↗
  7. Co-inhibition of RAGE and TLR4 sensitizes pancreatic cancer to irreversible electroporation in mice by disrupting autophagy. Co-author DOI 10.1038/s41401-025-01487-w↗
  8. Prospective assessment of pancreatic ductal adenocarcinoma diagnosis from endoscopic ultrasonography images with the assistance of deep learning. Last author DOI 10.1002/cncr.34772↗
  9. Advancements in SERS‐based biological detection and its application and perspectives in pancreatic cancer Last author DOI 10.1002/viw.20230070↗
  10. Combination therapy of irreversible electroporation and cytokine-induced killer cells for treating mice bearing panc02 pancreatic-cancer xenografts. Last author DOI 10.1016/j.bbrep.2023.101547↗
  11. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation. Co-author DOI 10.1021/acsnano.3c05009↗
  12. Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cas… Co-author DOI 10.1097/sla.0000000000005797↗
  13. Integrative Omics Analyses Reveal Molecular Changes of Irreversible Electroporation on Pancreatic cancer in Mice Last author DOI 10.21203/rs.3.rs-3167884/v1↗
  14. Single-cell analysis reveals nanosecond pulsed electric field ablation induced myeloid cells remodeling in pancreatic cancer. Last author DOI 10.1016/j.bioelechem.2022.108266↗
  15. Neutrophil membrane-coated nanoparticles for enhanced nanosecond pulsed electric field treatment of pancreatic cancer. Last author DOI 10.1080/02656736.2022.2093994↗
  16. Deep learning radiomics based on contrast-enhanced ultrasound images for assisted diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis. Last author DOI 10.1186/s12916-022-02258-8↗
  17. Corrigendum: Antitumor effect and immune response of nanosecond pulsed electric fields in pancreatic cancer. Last author DOI 10.3389/fonc.2022.1052763↗
  18. Deep learning for real-time auxiliary diagnosis of pancreatic cancer in endoscopic ultrasonography. Last author DOI 10.3389/fonc.2022.973652↗
  19. Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer. Last author DOI 10.1080/21655979.2021.1995581↗
  20. Immunomodulatory Effect of Irreversible Electroporation Alone and Its Cooperating With Immunotherapy in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.712042↗
  21. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer. Co-author DOI 10.4103/jcrt.jcrt_1663_20↗
  22. Antitumor Effect and Immune Response of Nanosecond Pulsed Electric Fields in Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.621092↗
  23. Endoscopic ultrasonography (EUS)-guided laser ablation (LA) of adrenal metastasis from pancreatic adenocarcinoma. Co-author DOI 10.1007/s10103-018-2449-1↗
  24. Irreversible Electroporation in Patients with Pancreatic Cancer: How Important Is the New Weapon? Last author DOI 10.1155/2018/5193067↗
  25. Pancreatic cancer: Does it work if EUS and laser ablation get married? Co-author DOI 10.4103/eus.eus_28_17↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guo Tian · 7 shared papers, 2018–2022 · strength 0.99
  2. Guoliang Qiao · 4 shared papers, 2025–2026 · strength 0.88
  3. Risheng Que · 3 shared papers, 2025–2026 · strength 0.61
  4. Tingbo Liang · 3 shared papers, 2025–2026 · strength 0.61
  5. Jun Zhao · 3 shared papers, 2022–2025 · strength 0.59
  6. Chengyue Zhang · 2 shared papers, 2026 · strength 0.57
  7. Lei Xu · 2 shared papers, 2023–2026 · strength 0.55
  8. Xueli Bai · 2 shared papers, 2026 · strength 0.48
  9. Jing Zhao · 3 shared papers, 2020–2022 · strength 0.43
  10. Xin Long · 2 shared papers, 2023–2025 · strength 0.43
  11. Tao Ma · 2 shared papers, 2023–2026 · strength 0.41
  12. Qi Zhang · 2 shared papers, 2023–2026 · strength 0.41
  13. Tingbo Liang · 2 shared papers, 2023–2026 · strength 0.41
  14. Xiang Li · 2 shared papers, 2025 · strength 0.39
  15. Qi Zhang · 2 shared papers, 2025 · strength 0.39
  16. Xueli Bai · 2 shared papers, 2025 · strength 0.39
  17. Huiyang Wang · 2 shared papers, 2021–2023 · strength 0.38
  18. Chengyu Fang · 2 shared papers, 2022–2023 · strength 0.37
  19. Jionghui Gu · 2 shared papers, 2022–2023 · strength 0.33
  20. Weilu Chai · 2 shared papers, 2018–2022 · strength 0.32
  21. Wenyuan Ma · 1 shared paper, 2026 · strength 0.32
  22. Cuifang Ye · 1 shared paper, 2025 · strength 0.27
  23. Xiang Li · 1 shared paper, 2026 · strength 0.26
  24. Xinhui Su · 1 shared paper, 2026 · strength 0.26
  25. Xiongbin Lu · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.